Female pattern hair loss: a pilot study investigating combination therapy with low-dose oral minoxidil and spironolactone.
증례연속
4/5 보강
TL;DR
Minoxidil and spironolactone are oral antihypertensives known to stimulate hair growth and may be useful in combination with other drugs to reduce the risk of hair loss.
📑 코퍼스 인용 관계
· 인용됨 44
📑 인용한 논문 (6) ▾
- Gender Differences in Adverse Effects and Dosing Practices of Low-Dose Oral Minoxidil for … Skin appendage disorders · 2025
- Expanding the therapeutic landscape of minoxidil for androgenetic alopecia: topical, oral … Frontiers in pharmacology · 2025
- Characterization and Management of Adverse Events of Low-Dose Oral Minoxidil Treatment for… Journal of clinical medicine · 2025
- Bicalutamide 25 mg combined with minoxidil 1 mg versus minoxidil 1 mg for female pattern h… JAAD international · 2025
- Characteristics of Hypertrichosis Induced by 24-week Low-dose (5 mg Daily) Oral Minoxidil … International journal of trichology · 2025
- The Requirement to Monitor Low-dose Oral Minoxidil in the Management of Hair Loss. International journal of trichology · 2025
연도별 인용 (2018–2026) · 합계 167
OpenAlex 토픽 ·
Hair Growth and Disorders
Hearing, Cochlea, Tinnitus, Genetics
Menopause: Health Impacts and Treatments
Abstract 🌐 Abstract
[BACKGROUND] Minoxidil and spironolactone are oral antihypertensives known to stimulate hair growth.
[OBJECTIVE] To report on a case series of women with pattern hair loss (PHL) treated with once daily minoxidil 0.25 mg and spironolactone 25 mg.
[METHODS] Women newly diagnosed with a Sinclair stage 2-5 PHL were scored for hair shedding and hair density before and after 12 months of treatment with oral minoxidil 0.25 mg and spironolactone 25 mg.
[RESULTS] A total of 100 women were included in this observational pilot study. Mean age was 48.44 years (range 18-80). Mean hair loss severity at baseline was Sinclair 2.79 (range 2-5). Mean hair shedding score at baseline was 4.82. Mean duration of diagnosis was 6.5 years (range 0.5-30). Mean reduction in hair loss severity score was 0.85 at 6 months and 1.3 at 12 months. Mean reduction in hair shedding score was 2.3 at 6 months and 2.6 at 12 months. Mean change in blood pressure was -4.52 mmHg systolic and -6.48 mmHg diastolic. Side effects were seen in eight women but were generally mild. No patients developed hyperkalemia or any other blood test abnormality. Six of these women continued treatment, and two women who developed urticaria discontinued treatment.
[LIMITATIONS] Prospective, uncontrolled, open-label observational study.
[DISCUSSION] Once daily capsules containing minoxidil 0.25 mg and spironolactone 25 mg appear to be safe and effective in the treatment of FPHL. Placebo-controlled studies to investigate this further are warranted.
[OBJECTIVE] To report on a case series of women with pattern hair loss (PHL) treated with once daily minoxidil 0.25 mg and spironolactone 25 mg.
[METHODS] Women newly diagnosed with a Sinclair stage 2-5 PHL were scored for hair shedding and hair density before and after 12 months of treatment with oral minoxidil 0.25 mg and spironolactone 25 mg.
[RESULTS] A total of 100 women were included in this observational pilot study. Mean age was 48.44 years (range 18-80). Mean hair loss severity at baseline was Sinclair 2.79 (range 2-5). Mean hair shedding score at baseline was 4.82. Mean duration of diagnosis was 6.5 years (range 0.5-30). Mean reduction in hair loss severity score was 0.85 at 6 months and 1.3 at 12 months. Mean reduction in hair shedding score was 2.3 at 6 months and 2.6 at 12 months. Mean change in blood pressure was -4.52 mmHg systolic and -6.48 mmHg diastolic. Side effects were seen in eight women but were generally mild. No patients developed hyperkalemia or any other blood test abnormality. Six of these women continued treatment, and two women who developed urticaria discontinued treatment.
[LIMITATIONS] Prospective, uncontrolled, open-label observational study.
[DISCUSSION] Once daily capsules containing minoxidil 0.25 mg and spironolactone 25 mg appear to be safe and effective in the treatment of FPHL. Placebo-controlled studies to investigate this further are warranted.
Minoxidil and spironolactone are oral antihypertensives known to stimulate hair growth and may be useful in combination with other drugs to reduce the risk of hair loss.
APA 7
Sinclair, R. D. (2018). Female pattern hair loss: A pilot study investigating combination therapy with low-dose oral minoxidil and spironolactone.. International journal of dermatology, 57(1), 104-109. https://doi.org/10.1111/ijd.13838
Vancouver
Sinclair RD. Female pattern hair loss: a pilot study investigating combination therapy with low-dose oral minoxidil and spironolactone. Inte. jour. derm.. 2018;57(1):104-109. doi:10.1111/ijd.13838
AMA 11
Sinclair RD. Female pattern hair loss: a pilot study investigating combination therapy with low-dose oral minoxidil and spironolactone. Inte. jour. derm.. 2018;57(1):104-109. doi:10.1111/ijd.13838
Chicago
Sinclair, R. D.. 2018. "Female pattern hair loss: a pilot study investigating combination therapy with low-dose oral minoxidil and spironolactone." International journal of dermatology 57 (1): 104-109. https://doi.org/10.1111/ijd.13838
MLA 9
Sinclair, R. D.. "Female pattern hair loss: a pilot study investigating combination therapy with low-dose oral minoxidil and spironolactone." International journal of dermatology, vol. 57, no. 1, 2018, pp. 104-109. doi:10.1111/ijd.13838.
PMID
29231239 ↗
추출된 의학 개체 (NER)
전체 NER 표 보기
| 유형 | 영어 표현 | 한국어 / 풀이 | UMLS CUI | 출처 | 등장 |
|---|---|---|---|---|---|
| 약물 | minoxidil
|
미녹시딜 | dict | 5 | |
| 질환 | female pattern hair loss
|
여성형 탈모 | dict | 1 |
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
인용 관계
그래프 OA 노드: 8/8 (100%)
· 참조 0편 · 후속 8편
이 논문을 인용한 후속 연구 20
- Treatment options for androgenetic alopecia: Efficacy, side effects, compliance, financial considera…
- Minoxidil and its use in hair disorders: a review.
- Androgenetic Alopecia: Therapy Update.
- Female pattern hair loss: A clinical, pathophysiologic, and therapeutic review.
- Treatment of Androgenetic Alopecia: Current Guidance and Unmet Needs.
- Efficacy and Safety of Oral Minoxidil 5 mg Once Daily in the Treatment of Male Patients with Androge…
- Prevention and Treatment of Chemotherapy-Induced Alopecia: What Is Available and What Is Coming?
- Clinical and preclinical approach in AGA treatment: a review of current and new therapies in the reg…
- Advances in hair growth.
- Recent Advances in Understanding of the Etiopathogenesis, Diagnosis, and Management of Hair Loss Dis…
- Female Pattern Hair Loss-An Update.
- The Efficacy and Safety of Oral and Topical Spironolactone in Androgenetic Alopecia Treatment: A Sys…
- Female-pattern hair loss: therapeutic update.
- Oral minoxidil use in androgenetic alopecia and telogen effluvium.
- Eyebrow Regrowth in Patients with Frontal Fibrosing Alopecia Treated with Low-Dose Oral Minoxidil.
- Low-Dose Oral Minoxidil for Alopecia: A Comprehensive Review.
- Current and emerging treatment strategies for hair loss in women of color.
- The Efficacy and Safety of Oral Spironolactone in the Treatment of Female Pattern Hair Loss: A Syste…
- Understanding Pattern Hair Loss-Hair Biology Impacted by Genes, Androgens, Prostaglandins and Epigen…
- Effect of Oral Minoxidil for Alopecia: Systematic Review.
같은 제1저자의 인용 많은 논문 (3)
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- COVID-19의 50가지 이상의 장기 후유증: 체계적 문헌고찰 및 메타분석.
- 미국 임상내분비학회, 미국 내분비학회, 안드로겐 과다 및 PCOS 학회 질환 임상 리뷰: 다낭성 난소 증후군의 평가와 치료를 위한 최선의 진료 지침--1부.
- 임상 진료. 다낭성 난소 증후군.
- PCOS의 유전적, 호르몬적, 대사적 측면: 최신 동향.
- Rochester Epidemiology Project(1990-2009)에서 추정된 원형 탈모의 평생 발병 위험도는 2.1%이다.
- 폐경전 여성의 다모증 평가 및 치료: Endocrine Society 임상진료지침.
📖 비슷한 OA 논문 — 같은 카테고리, 무료 전문 가능
-
Treatment options for androgenetic alopecia: Efficacy, side effects, compliance, financial considerations, and ethics.
TL;DRAlthough a variety of medical, surgical, light‐based and nutraceutical treatment options are available to slow or reverse the progression of AGA, it can be challenging to select ap…
-
Minoxidil and its use in hair disorders: a review.
TL;DRThis article aims to review and update current information on the pharmacology, mechanism of action, clinical efficacy, and adverse events of topical minoxidil.
-
Androgenetic Alopecia: Therapy Update.
TL;DRThis comprehensive review discusses the evaluation of AGA and the mechanisms of action, costs, efficacies, and safety profiles of existing, alternative, and upcoming therapeutics f…
-
Treatment of alopecia areata: An Australian expert consensus statement.
TL;DRThe purpose of this consensus statement is to outline a treatment algorithm for AA, including the indications for systemic treatment, appropriate choice of systemictreatment, satis…
-
Telogen Effluvium: A Review of the Literature.
TL;DRIn the treatment of telogen effluvium, it is essential to identify and remove the causative factors and to use drugs such as corticosteroids, minoxidil, and novel treatments such a…